Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:OCAT
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $8.42
- 200 Day Moving Avg: $6.15
- 52 Week Range: $3.06 - $8.71
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.29
- P/E Growth: 0.00
- Average Volume: 830,858 shs.
Frequently Asked Questions for Ocata Therapeutics (NASDAQ:OCAT)
What is Ocata Therapeutics' stock symbol?
Ocata Therapeutics trades on the NASDAQ under the ticker symbol "OCAT."
How were Ocata Therapeutics' earnings last quarter?
Ocata Therapeutics Inc (NASDAQ:OCAT) announced its earnings results on Thursday, August, 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The company had revenue of $0.04 million for the quarter. View Ocata Therapeutics' Earnings History.
Who are some of Ocata Therapeutics' key competitors?
Some companies that are related to Ocata Therapeutics include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy Ocata Therapeutics stock?
Shares of Ocata Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ocata Therapeutics stock cost?
One share of Ocata Therapeutics stock can currently be purchased for approximately $8.47.
Earnings History for Ocata Therapeutics (NASDAQ:OCAT)Earnings History by Quarter for Ocata Therapeutics (NASDAQ:OCAT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Ocata Therapeutics (NASDAQ:OCAT)
Current Year EPS Consensus Estimate: $-0.60 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS
Dividend History for Ocata Therapeutics (NASDAQ:OCAT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ocata Therapeutics (NASDAQ:OCAT)Insider Trades by Quarter for Ocata Therapeutics (NASDAQ:OCAT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/10/2015||Robert Lanza||insider||Sell||35,000||$8.31||$290,850.00|| |
Headline Trends for Ocata Therapeutics (NASDAQ:OCAT)
Latest Headlines for Ocata Therapeutics (NASDAQ:OCAT)
Ocata Therapeutics (OCAT) Chart for Saturday, May, 27, 2017